On Wednesday September 24, Ori’s CEO Jason C. Foster led an expert panel in Boston titled The CGT Success Blueprint: Strategic collaboration, best-of-breed technology, and scientific excellence.
He was joined by Dr. Bruce Thompson (Kincell Bio), Lucy Foley (eXmoor Pharma), Aaron Vernon (Quell Therapeutics), and Dr. Magdi Elsallab (Mass General Cancer Center). Together they explored how partnerships, modular platforms, and advanced manufacturing are shaping the future of cell and gene therapy.
A huge thank you to our panelists, partners, and colleagues who made our Boston CGT Collaboration Evening such a success.
Key takeaways from the discussion:
- Flexibility is key – best-of-breed, modular platforms let developers protect the biology and iterate faster
- Scalability starts early – decisions in early development define timelines, costs, and commercial viability
- Early automation pays off – reducing variability and increasing throughput without compromising science
- Ecosystems must adapt to the science – academic centers, CDMOs, and developers need shared analytics, clear roles, and strong process control
A special thank you to Gary Fey, who has been living with multiple myeloma for nine years, and his wife Meg Lindsay. Their story of resilience and the life-changing potential of CAR-T therapy was a powerful reminder of why we do this work.
We left inspired and more certain than ever that the future of CGT manufacturing will be defined by collaboration, new technologies, and putting patients at the center.
